HOME
ABOUT
About Adial
Management
Board of Directors
ADDICTION
Alcohol Addiction
Limitations of Current AUD Therapies
Our Proposed Solution
TECHNOLOGY
Overview
Phase 2b Clinical Trial Results
History of Ondansetron Use for AUD
Strengths and Competitive Advantages
Newsroom
Press Releases
Media
INVESTORS
Overview
Analyst Coverage
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
CONTACT
Contact Us
Sign up for email alerts
HOME
ABOUT
About Adial
Management
Board of Directors
ADDICTION
Alcohol Addiction
Limitations of Current AUD Therapies
Our Proposed Solution
TECHNOLOGY
Overview
Phase 2b Clinical Trial Results
History of Ondansetron Use for AUD
Strengths and Competitive Advantages
Newsroom
Press Releases
Media
INVESTORS
Overview
Analyst Coverage
News / Events
Company Information
Financial Information
Stock Data
SEC Filings
Corporate Governance
CONTACT
Contact Us
Sign up for email alerts
Investor Relations
16129
page-template-default,page,page-id-16129,bridge-core-2.5.8,ajax_fade,page_not_loaded,,qode-theme-ver-24.3,qode-theme-bridge,disabled_footer_top,qode_header_in_grid,wpb-js-composer js-comp-ver-6.4.2,vc_responsive
Investor Relations
COMING SOON
For further information please Contact:
[email protected]